Ophthalmic Drug Solutions

Ophthalmic Drug Delivery

Delivery of therapeutics to the human eye is one of the most interesting, but challenging, endeavors a formulator can take on. The anatomy and chemical composition of the eye make it highly resistant to pharmaceutical penetration. Successfully circumventing these protective barriers requires a partner with intimate knowledge of ocular drug delivery as well as specialized development and manufacturing expertise.
 
LLS Health is well-equipped to meet your needs for ophthalmic drug delivery, in both the anterior and posterior segments of the eye. We provide pharmaceutical excipients ideal for overcoming the complex drug delivery challenges presented by the human eye, as well as contract development and manufacturing (CDMO) services.
 
Our Carbopol®, Pemulen and Noveon® polymers are versatile and efficient in complex topical mucosal formulations. These monograph-compliant, mucoadhesive excipients are compatible with most active pharmaceutical ingredients (APIs) and provide essential properties for effective ocular delivery, including:
  • Bioadhesion / Mucoadhesion – maximize drug absorption by prolonging contact time with the eye, which can increase bioavailability, reduce dosing frequency, and subsequently improve patient compliance
  • Versatility – compatible with a wide variety of acidic, basic, and neutral APIs across a broad pH range while providing customizable rheology and viscosity for your product
  • Emulsification – ability to suspend oils in solution and suitable salt tolerance, which are important qualities for many topical products such as eye drops
  • Non-irritating and non-toxic  enhances patient comfort and safety
Our Pathway thermoplastic polyurethane (TPU) excipients are well suited for drug device combination products, including implants and punctal plugs. These products can have unique benefits such as localized therapeutic release and delivery to the posterior part of the eye, a common obstacle. Additionally, non-biodegradable polymers such as TPU have been shown to provide better control of drug release than their biodegradable counterparts and have the distinct advantage of functioning over longer time periods.
 
The CDMO division of LLS Health has over 20 years of helping formulators by working with complex drug products, including intravitreal injectables, topical suspensions, and ocular implants, among others, and are experts in ophthalmic drug development